Syndax Pharmaceuticals (SNDX) – Momentum Movers
-
Syndax Pharmaceuticals (SNDX) Climbs 14% Following Positive Results form Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
-
Syndax Pharmaceuticals (SNDX) Surges as NSCLS Treatment Advances to Phase 2 Trials
Back to SNDX Stock Lookup